Published in Lab Business Week, October 14th, 2007
In this Merck trial involving high risk volunteers, an equal number of people received either placebo or AIDS vaccine. The independent Data Safety Monitoring Board recommended that the trial be stopped because it was not reaching its efficacy endpoints.
Merck has stopped further vaccinations but will continue to follow volunteers in the trial. The Merck trial was being carried out in conjunction with the HIV Vaccine Trials Network...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week